Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations-10 Children and Review of the Literature
[Introduction] Since the first description of gain of function (GOF) mutations in signal transducer and activator of transcription (STAT) 1, more than 300 patients have been described with a broad clinical phenotype including infections and severe immune dysregulation. Whilst Jak inhibitors (JAKinib...
| Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Status: | Published version |
| Publication Date: | 2022 |
| Country: | España |
| Institution: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repository: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/306359 |
| Online Access: | http://hdl.handle.net/10261/306359 https://api.elsevier.com/content/abstract/scopus_id/85129184839 |
| Access Level: | Open access |
| Keyword: | Baricitinib Children Chronic mucocutaneous candidiasis Inborn errors of immunity JAK inhibitors JAK-STAT pathway Pediatrics Primary immunodeficiency disease Ruxolitinib STAT1 GOF http://metadata.un.org/sdg/3 http://metadata.un.org/sdg/4 Ensure healthy lives and promote well-being for all at all ages Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all |
| Summary: | [Introduction] Since the first description of gain of function (GOF) mutations in signal transducer and activator of transcription (STAT) 1, more than 300 patients have been described with a broad clinical phenotype including infections and severe immune dysregulation. Whilst Jak inhibitors (JAKinibs) have demonstrated benefits in several reported cases, their indications, dosing, and monitoring remain to be established. |
|---|